15 October 2021>: Clinical Research
The Serum Metabolomics Study of Liver Failure and Artificial Liver Therapy Intervention
Shipeng Huang 1ABC , Dali Hu 2BCD , Songsong Yuan 2BCD , Ying He 2BCD , Chengmu Li 2BCD , Ying Zhu 2BCD , Xiaoping Wu 2AEF*DOI: 10.12659/MSM.930638
Med Sci Monit 2021; 27:e930638
Table 1 General data and clinical characteristics of the patients.
Healthy control group (n=32) | Liver failure group (n=50) | Chronic hepatitis group (n=30) | Liver failure artificial liver therapy group (n=11) | Pa | Pb | Pc | P | |
---|---|---|---|---|---|---|---|---|
MF | 15/17 | 23/27 | 14/16 | 7/4 | 0.991 | 0.938 | 0.954 | 0.987 |
Age (years) | 44.3±5.5 | 44.5±12.2 | 43.5±3.9 | 46.7±4.6 | 0.884 | 0.938 | 0.631 | 0.710 |
ALT (U/L) | 27.6±23.8 | 773.2±768.2 | 83.3±36.7 | 676.6±699.3 | 0.666 | |||
AST (U/L) | 25.3±11.5 | 440.0±420.0 | 48.3±25.4 | 501.8±503.6 | 0.745 | |||
TBiL (umol/L) | 12.1±5.7 | 278.5±131.7 | 14.1±5.9 | 297.0±152.3 | 0.929 | |||
ALB (g/L) | 43.4±2.9 | 35.9±20.8 | 46.2±3.2 | 30.4±4.1 | 0.004 | 0.018 | 0.002 | 0.433 |
The results were expressed as mean±standard deviation. Pa – liver failure group vs healthy control group; Pb – liver failure group vs chronic hepatitis group; Pc – chronic hepatitis group vs healthy control group; P – liver failure artificial liver therapy group vs liver failure group. P |